Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones

Antiviral Therapy

Volumn 17, Issue 3, 2012, Pages 495-507

  McGee, Kirsty C ^a   Shahmanesh, Mohsen ^b   Boothby, Meg ^b   Nightingale, Peter ^c   Gathercole, Laura L ^c   Tripathi, Gyanendra ^a   Harte, Alison L ^a   Shojaee Moradie, Fariba ^d   Umpleby, A Margot ^d   Das, Satyajit ^b   Al Daghri, Nasser M ^e   McTernan, Philip G ^a   Tomlinson, Jeremy W ^c  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF SURREY   (United Kingdom)

^e KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; CYTOCHROME C OXIDASE; CYTOCHROME C OXIDASE 4; CYTOCHROME OXIDASE B; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FATTY ACID BINDING PROTEIN 4; FATTY ACID SYNTHASE; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HORMONE SENSITIVE LIPASE; LAMIVUDINE PLUS ZIDOVUDINE; LIPOPROTEIN LIPASE; LOPINAVIR PLUS RITONAVIR; NUCLEAR RESPIRATORY FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL FUMARATE PLUS ZIDOVUDINE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2; UNCOUPLING PROTEIN 3;

ADULT; ANAEROBIC METABOLISM; ARTICLE; BODY FAT; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; LIPID METABOLISM; MALE; MITOCHONDRIAL RESPIRATION; PRIORITY JOURNAL; SUBCUTANEOUS FAT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPREGULATION;

ADENINE; ADIPOSE TISSUE; ADULT; ANAEROBIOSIS; ANTI-HIV AGENTS; BENZOXAZINES; DRUG THERAPY, COMBINATION; ELECTRON TRANSPORT COMPLEX IV; FEMALE; GENE EXPRESSION REGULATION; HIV INFECTIONS; HIV-1; HUMANS; ION CHANNELS; LIPOGENESIS; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 84861708561     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2017     Document Type: Article

References (57)

1. Giralt M, Domingo P, Guallar JP, et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy. Antivir Ther 2006; 11:729-740. (Pubitemid 44497168)
2. Hammond E, Nolan D, James I, Metcalf C, Mallal S. Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy. AIDS 2004; 18:815-817. (Pubitemid 38535012)
3. Miró O, López S, Pedrol E, et al. Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy. Antivir Ther 2003; 8:333-338. (Pubitemid 37101637)
4. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58. (Pubitemid 28190689)
5. Shlay JC, Sharma S, Peng G, Gibert CL, Grunfeld C. Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine. J Acquir Immune Defic Syndr 2008; 48:53-62. (Pubitemid 351600854)
6. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47:74-78. (Pubitemid 351619372)
7. Boothby M, McGee KC, Tomlinson JW, et al. Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther 2009; 14:1089-1100.
8. Kratz M, Purnell JQ, Breen PA, et al. Reduced adipogenic gene expression in thigh adipose tissue precedes human immunodeficiency virus-associated lipoatrophy. J Clin Endocrinol Metab 2008; 93:959-966. (Pubitemid 351398580)
9. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17:971-979. (Pubitemid 36549708)
10. Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006; 43:458-466. (Pubitemid 44737105)
11. Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21:2445-2453. (Pubitemid 350145176)
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419. (Pubitemid 15018832)
13. Tomlinson JW, Walker EA, Bujalska IJ, et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004; 25:831-866. (Pubitemid 39366049)
14. Lavery GG, Walker EA, Draper N, et al. Hexose-6-phosphate dehydrogenase knock-out mice lack 11 beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. J Biol Chem 2006; 281:6546-6551. (Pubitemid 43847588)
15. McComsey GA, Paulsen DM, Lonergan JT, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19:15-23. (Pubitemid 40111014)
16. Spiegelman BM, Puigserver P, Wu Z. Regulation of adipogenesis and energy balance by PPARgamma and PGC-1. Int J Obes Relat Metab Disord 2000; 24 Suppl 4:S8-S10.
17. Scarpulla RC. Nuclear control of respiratory gene expression in mammalian cells. J Cell Biochem 2006; 97:673-683.
18. Cannino G, Di Liegro CM, Rinaldi AM. Nuclear-mitochondrial interaction. Mitochondrion 2007; 7:359-366. (Pubitemid 350082356)
19. Nolan D, Mallal S. Antiretroviral-therapy-associated lipoatrophy: current status and future directions. Sex Health 2005; 2:153-163.
20. Rousset S, Alves-Guerra MC, Mozo J, et al. The biology of mitochondrial uncoupling proteins. Diabetes 2004; 53 Suppl 1:S130-S135. (Pubitemid 38168705)
21. Chevillotte E, Giralt M, Miroux B, Ricquier D, Villarroya F. Uncoupling protein-2 controls adiponectin gene expression in adipose tissue through the modulation of reactive oxygen species production. Diabetes 2007; 56:1042-1050. (Pubitemid 46525055)
22. Lagathu C, Eustace B, Prot M, et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 2007; 12:489-500. (Pubitemid 47041147)
23. Pace CS, Martin AM, Hammond EL, Mamotte CD, Nolan DA, Mallal SA. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther 2003; 8:323-331. (Pubitemid 37101636)
24. Kannisto K, Sutinen J, Korsheninnikova E, et al. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 2003; 17:1753-1762. (Pubitemid 37000093)
25. Medina-Gomez G, Gray S, Vidal-Puig A. Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgamma coactivator-1 (PGC1). Public Health Nutr 2007; 10:1132-1137. (Pubitemid 350085201)
26. Caron M, Auclair M, Lagathu C, et al. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004; 18:2127-2136. (Pubitemid 39463677)
27. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288:207-215. (Pubitemid 34755281)
28. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18:1029-1036. (Pubitemid 38591194)
29. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43:535-540. (Pubitemid 44885619)
30. Pérez-Molina JA, Domingo P, Martínez E, Moreno S. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy. J Antimicrob Chemother 2008; 62:234-245. (Pubitemid 351984766)
31. De Pauw A, Tejerina S, Raes M, Keijer J, Arnould T. Mitochondrial (dys)function in adipocyte (de) differentiation and systemic metabolic alterations. Am J Pathol 2009; 175:927-939.
32. Dubé MP, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 2007; 45:508-514. (Pubitemid 47294922)
33. Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci 2003; 24:276-283. (Pubitemid 36725002)
34. Deveaud C, Beauvoit B, Hagry S, et al. Site specific alterations of adipose tissue mitochondria in 3′-azido-3′-deoxythymidine (AZT)-treated rats: an early stage in lipodystrophy? Biochem Pharmacol 2005; 70:90-101. (Pubitemid 40803449)
35. Kosmiski LA, Bacchetti P, Kotler DP, et al. Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab 2008; 93:216-224.
36. Caron M, Vigouroux C, Bastard JP, Capeau J. Adipocyte dysfunction in response to antiretroviral therapy: clinical, tissue and in-vitro studies. Curr Opin HIV AIDS 2007; 2:268-273. (Pubitemid 46941818)
37. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-1115. (Pubitemid 29452832)
38. Zaera MG, Miró O, Pedrol E, et al. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS 2001; 15:1643-1651. (Pubitemid 32918117)
39. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-1031. (Pubitemid 34286541)
40. Garcia A, Victor VM, Gomez-Soler M, Gomes-Sucerquia LJ, Apostolova N, Esplugues JV. EFV-induced reduction of mitochondrial respiration is due to inhibition of complex I. Antivir Ther 2009; 14 Suppl 2:A61.
41. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23:1109-1118.
42. Puls RL, Srasuebkul P, Petroumenos K, Emery S, Cooper DA. Anthropometric and metabolic outcomes in a 48-week randomised, open-label study of three different combination antiretroviral regimens as initial therapy for HIV infection. Antivir Ther 2009; 14 Suppl 2:A8.
43. Moyle G, Givens N, Pearce H, Compston J. Effects of ART on bone turnover markers and bone density in HIV-infected patients. Antivir Ther 2009; 14 Suppl 2:A14.
44. Fleury C, Mignotte B, Vayssière JL. Mitochondrial reactive oxygen species in cell death signaling. Biochimie 2002; 84:131-141. (Pubitemid 34946949)
45. Mazat JP, Rossignol R, Malgat M, Rocher C, Faustin B, Letellier T. What do mitochondrial diseases teach us about normal mitochondrial functions...that we already knew: threshold expression of mitochondrial defects. Biochim Biophys Acta 2001; 1504:20-30. (Pubitemid 32179655)
46. Lenaz G, Baracca A, Carelli V, D'Aurelio M, Sgarbi G, Solaini G. Bioenergetics of mitochondrial diseases associated with mtDNA mutations. Biochim Biophys Acta 2004; 1658:89-94. (Pubitemid 39013238)
47. El Hadri K, Glorian M, Monsempes C, et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J Biol Chem 2004; 279:15130-15141. (Pubitemid 38618908)
48. Gallego-Escuredo JM, Del Mar Gutierrez M, Diaz-Delfin J, et al. Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. Curr HIV Res 2010; 8:545-553.
49. Caron M, Auclairt M, Vissian A, Vigouroux C, Capeau J. Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Antivir Ther 2008; 13:27-38. (Pubitemid 351541671)
50. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8:729-740. (Pubitemid 47312822)
51. Campisi J, Vijg J. Does damage to DNA and other macromolecules play a role in aging? If so, how? J Gerontol A Biol Sci Med Sci 2009; 64A:175-178.
52. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179-1184. (Pubitemid 40720744)
53. Law MG, D'Armino Monforte A, Friis-Moller N, et al. Cardio- and cerebrovascular events and predicted rates of myocardial infarction in the D:A:D Study. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Fransisco, CA USA. Abstract 737.
54. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22:2409-2418.
55. Currier JS, Boyd F, Kawabata H, Dezii C, Burtcel B, Hodder S. Diabetes mellitus and HIV infection. 9th Conference on Retroviruses and Opportunistic Infected Individuals. 24-28 February 2002. Abstract 677-T.
56. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506-512. (Pubitemid 36886080)
57. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005; 39:44-54. (Pubitemid 40617018)